The impact of stage and histology on the long-term clinical course of 163,808 patients with breast carcinoma

Cancer

Volumn 77, Issue 8, 1996, Pages 1459-1464

  Gamel, John W ^a,d   Meyer, John S ^b   Feuer, Eric ^c   Miller, Barry A ^c  

^a University of Louisville School of Medicine   (United States)

^b ST LUKE S HOSPITAL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NONE   (United States)

Author keywords

breast cancer; cured fraction; histologic type; stage; survival time

Indexed keywords

ARTICLE; BREAST CARCINOMA; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDULLARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOPLASM STAGING; PROGNOSIS; SEER PROGRAM; SURVIVAL ANALYSIS;

EID: 0029928658     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960415)77:8<1459::AID-CNCR6>3.0.CO;2-7     Document Type: Article

References (17)

1. Henson DE, Ries L, Shambaugh EM. Survival results depend on the staging system. Semin Surg Oncol 1992;8:57-61.
2. Boag JW. Maximum likelihood estimates of the proportion of patients cured by cancer therapy. J Royal Stat Soc 1949;11:15-44.
3. Mould RF, Boag JW. A test of several parametric statistical models for estimating success rate in the treatment of carcinoma cervix uteri. Br J Cancer 1975;32:529-50.
4. Rutqvist LE, Wallgren A, Nilsson B. Is breast cancer a curable disease? A study of 14,731 women with breast cancer from the cancer registry of Norway. Cancer 1984;53:1793-800.
5. Gamel J, McLean I. A stable multivariate extension of the log normal survival model. Comp Biomed Res 1994;27:148-55.
6. Gamel JW, Vogel RL, Valagussa P, Bonadonna G. Parametric survival analysis of adjuvant therapy for stage 2 breast cancer. Cancer 1994;74:2483-90.
7. Beahrs OH, Henson DE, Hutter RW, Kennedy BJ, editor. Manual for Staging of Cancer. 4th ed. Philadelphia: JB Lippincott, 1992:152.
8. McDivitt RW, Stewart FW, Berg JW. Tumors of the Breast. Washington, D.C.: Armed Forces Institute of Pathology, 1968;54-5.
9. Azzopoardi JH, Ahmed A, Millis RR. Problems in Breast Pathology. Philadelphia: W.B. Saunders Co. Ltd., 1979:128.
10. Page DL, Anderson TJ. Diagnostic histopathology of the breast. Edinburgh: 1987;157-62.
11. Rosen PP, Oberman HA. Atlas of Tumor Pathology. Tumors of the Mammary Gland. Washington, D.C.: Armed Forces Institute of Pathology, 1993;148.
12. Rapin V, Contesso G, Mouriesse H, Bertin F, Lacombe MJ, Piekarski JD, et al. Medullary breast carcinoma. A reevaluation of 95 cases of breast cancer with inflammatory stroma. Cancer 1988;61:2503-10.
13. Meyer JS, Prey MU, Babcock DS, McDivitt RW. Breast carcinoma cell kinetics, morphology, stage and host characteristics. Lab Invest 1986;54:41-51.
14. Meyer JS. Cell kinetics of histologic variants of in-situ breast carcinoma. Breast Carcinoma Res Treat 1986;7:171-80.
15. Meyer JS, McDivitt RW. Reliability and stability of the thymidine labeling index of breast carcinoma. Lab Invest 1986;54:160-4.
16. Hupperets PS, Schutte B, van Assche C, Schouten LJ, Jager J, deJong J, et al. Ploidyand S-phase fractions (SPF) of primary breast cancers and their nodal metastases. Breast Cancer Res Treat 1994;32:197-202.
17. Meyer JS, Province MA. S-phase fraction (SPF) and nuclear size in long term prognosis of breast carcinoma. Cancer 1994;74:2287-99.